Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Connective and Soft Tissue Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Connective and Soft Tissue Neoplasm

Cancer Family

Connective and Soft Tissue Neoplasm

CI-CAN-00000010Explore in graph →

Non-malignant848 active trials17 approved drugs339 evidence items

NCIt: C3810
MeSH: D018204

Overview
Statistics
Survival
Genomics24
Variants & evidence339
Drugs43
Trials3877
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (225)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 225 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
· Genes Chromosomes Cancer · 2014 · PMID 24824843 · validated civic_curation pubmed
Clinicopathologic features and molecular spectrum of spindle cell and sclerosing rhabdomyosarcomas in the head and neck region.
· Int J Clin Exp Pathol · 2018 · PMID 31949721 · validated civic_curation pubmed
Recurrent rearrangements of FOS and FOSB define osteoblastoma.
· Nat Commun · 2018 · PMID 29858576 · validated civic_curation pubmed
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
· Cancer Discov · 2014 · PMID 24436047 · validated cbioportal_study pubmed
Evolving classification of rhabdomyosarcoma.
· Histopathology · 2022 · PMID 34958505 · validated civic_curation pubmed
Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.
· Am J Surg Pathol · 2007 · PMID 17721195 · validated civic_curation pubmed
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Showing 51–75 of 225 publications

← Previous
1
2
3
4
…
9
Next →

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.

· Mod Pathol · 2007 · PMID 17334349 · validated civic_curation pubmed

Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays.

· Hum Pathol · 2011 · PMID 21111450 · validated civic_curation pubmed

Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma Harboring ZFP64::NCOA2/3 Fusions: A Series of 14 Cases.

· Mod Pathol · 2025 · PMID 41075874 · validated civic_curation pubmed

Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.

· J Pathol Clin Res · 2015 · PMID 27499898 · validated civic_curation pubmed

Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.

· Mod Pathol · 2019 · PMID 30459475 · validated civic_curation pubmed

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.

· Lab Invest · 2004 · PMID 15146165 · validated civic_curation pubmed

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

· Clin Cancer Res · 2006 · PMID 16551858 · validated civic_curation pubmed

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

· Clin Cancer Res · 2006 · PMID 16638875 · validated civic_curation pubmed

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

· Am J Pathol · 2002 · PMID 12000708 · validated civic_curation pubmed

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

· Cancer Res · 1999 · PMID 10485475 · validated civic_curation pubmed

SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.

· N Engl J Med · 1998 · PMID 9428816 · validated civic_curation pubmed

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

· BMC Cancer · 2012 · PMID 22439647 · validated civic_curation pubmed

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

· J Clin Oncol · 2013 · PMID 23569312 · validated civic_curation pubmed

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

· J Clin Oncol · 2008 · PMID 18955458 · validated civic_curation pubmed

Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors.

· Mod Pathol · 2006 · PMID 16258512 · validated civic_curation pubmed

Molecular genetic characterization of the genomic ACTB-GLI fusion in pericytoma with t(7;12).

· Biochem Biophys Res Commun · 2004 · PMID 15555571 · validated civic_curation pubmed

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

· JAMA Oncol · 2016 · PMID 27124835 · validated civic_curation pubmed

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

· Ann Oncol · 2016 · PMID 27371698 · validated civic_curation pubmed